The Hypercholesterolemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hypercholesterolemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypercholesterolemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued products.

GlobalData tracks 129 drugs in development for Hypercholesterolemia by 107 companies/universities/institutes. The top development phase for Hypercholesterolemia is preclinical with 42 drugs in that stage. The Hypercholesterolemia pipeline has 117 drugs in development by companies and 12 by universities/ institutes. Some of the companies in the Hypercholesterolemia pipeline products market are: Nyrada, iMetabolic Biopharma and Verve Therapeutics.

The key targets in the Hypercholesterolemia pipeline products market include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.), 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC, and Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3).

The key mechanisms of action in the Hypercholesterolemia pipeline product include Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) Inhibitor with 35 drugs in Pre-Registration. The Hypercholesterolemia pipeline products include 11 routes of administration with the top ROA being Oral and 13 key molecule types in the Hypercholesterolemia pipeline products market including Small Molecule, and Monoclonal Antibody.

Hypercholesterolemia overview

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads to the formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing a heart attack or stroke. Two forms of the condition exist: heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obesity, family history, high blood pressure, smoking, and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives, and cholesterol absorption inhibitors.

For a complete picture of Hypercholesterolemia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.